Study of TLL-018 for rheumatoid arthritis after standard treatments fail
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests an investigational drug called TLL-018 for people with moderate to severe rheumatoid arthritis who have not improved enough with standard disease-modifying drugs. It aims to see if the drug can reduce joint pain and swelling.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with rheumatoid arthritis for at least 3 months.
- You have at least 6 swollen and 6 tender joints.
- You have tried at least one standard treatment (like methotrexate) for at least 3 months, but it hasn't worked well enough.
- Your blood tests show you have inflammation and your liver, kidney, and blood cell counts are within acceptable levels.
- You agree to use effective birth control (if applicable) and not to donate sperm or eggs during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't been controlled by multiple standard treatments. It aims to see if telitacicept can help reduce inflammation and improve symptoms.
This trial tests an investigational drug called JAB-8263 for people with active rheumatoid arthritis. It aims to see if the drug can help reduce inflammation and improve symptoms.
This trial tests an experimental tablet, TollB-001, for people with moderate to severe rheumatoid arthritis who have not responded well to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new medicine called CLN-978, given as an injection under the skin, to see if it can help people with active rheumatoid arthritis who haven't improved enough with other treatments. CLN-978 works by targeting a specific immune cell to reduce inflammation.
This trial tests a new drug called A-319 for people with active rheumatoid arthritis (RA) that hasn't improved enough after trying other treatments. The goal is to see if A-319 can reduce joint pain, swelling, and inflammation.
This trial tests an investigational drug, QLS12010, for people with moderate-to-severe rheumatoid arthritis who have not improved enough after trying at least two other types of RA medications.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.